Media coverage about Tetraphase Pharmaceuticals (NASDAQ:TTPH) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.4621274777242 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s rankings:
- Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society (finance.yahoo.com)
- Tetraphase Pharmaceuticals’ Cash Flow and Price Performance (finance.yahoo.com)
- A Look at Tetraphase Pharmaceuticals’ Target Market (finance.yahoo.com)
- Exploring Tetraphase Pharmaceuticals’ Financial Performance (finance.yahoo.com)
- EPS for Tetraphase Pharmaceuticals, Inc. (TTPH) Expected At $-0.47 on May, 3 (fanob.com)
Shares of TTPH stock traded down $0.09 during trading hours on Monday, reaching $3.14. The company had a trading volume of 570,251 shares, compared to its average volume of 1,434,733. Tetraphase Pharmaceuticals has a 12 month low of $2.05 and a 12 month high of $8.75. The firm has a market capitalization of $166.65, a PE ratio of -1.19 and a beta of 2.61.
A number of brokerages have recently issued reports on TTPH. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. BidaskClub cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Piper Jaffray reaffirmed an “overweight” rating and set a $8.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. BMO Capital Markets cut Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Wednesday, February 14th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $7.22.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the sale, the insider now directly owns 8,750 shares in the company, valued at $54,425. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.50% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.